Rigel Pharmaceuticals (RIGL) Share-based Compensation Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.54% |
| Dec 31, 2025 | 11.01% |
| Sep 30, 2025 | 12.29% |
| Jun 30, 2025 | 13.27% |
| Mar 31, 2025 | 10.43% |
| Dec 31, 2024 | 8.14% |
| Sep 30, 2024 | 4.73% |
| Jun 30, 2024 | -0.96% |
| Mar 31, 2024 | 11.70% |
| Dec 31, 2023 | -1.24% |
| Sep 30, 2023 | -8.29% |
| Jun 30, 2023 | 14.33% |
| Mar 31, 2023 | 12.36% |
| Dec 31, 2022 | 5.93% |
| Sep 30, 2022 | 25.40% |
| Jun 30, 2022 | 16.80% |
| Mar 31, 2022 | 27.41% |
| Dec 31, 2021 | 16.29% |
| Sep 30, 2021 | 5.14% |
| Jun 30, 2021 | 2.74% |
| Mar 31, 2021 | 12.91% |
| Dec 31, 2020 | 0.06% |
| Sep 30, 2020 | 0.75% |
| Jun 30, 2020 | -1.65% |
| Mar 31, 2020 | -0.29% |
| Dec 31, 2019 | -1.22% |
| Sep 30, 2019 | 0.17% |
| Jun 30, 2019 | 4.47% |
| Mar 31, 2019 | 4.55% |
| Dec 31, 2018 | 5.65% |
| Sep 30, 2018 | 65.81% |
| Jun 30, 2018 | -8.64% |
| Mar 31, 2018 | -3.00% |
| Dec 31, 2017 | -1.28% |
| Sep 30, 2017 | -23.09% |
| Jun 30, 2017 | -18.24% |
| Mar 31, 2017 | -20.97% |
| Dec 31, 2016 | -18.40% |
| Sep 30, 2016 | -11.12% |
| Jun 30, 2016 | -8.84% |
| Mar 31, 2016 | -17.82% |
| Dec 31, 2015 | -15.63% |
| Sep 30, 2015 | -13.59% |